Company Profile
TELA Bio Stock Price, News & Analysis
Company overview
Business overview
TELA Bio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, TELA Bio is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
TELA Bio follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, TELA Bio sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
TELA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
TELA Bio's story is really about the OviTex portfolio. OviTex PRS is still the core reconstruction product, while OviTex Inguinal and OviTex LPR give the company more specific ways to build around hernia repair and broader soft-tissue reconstruction. The next question is whether that portfolio keeps gaining surgeon adoption enough to feel embedded in routine practice.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
TELA Bio Reports First Quarter 2026 Financial Results
Source: TELA Bio
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.